Exact Mass: 483.1188432000001

Exact Mass Matches: 483.1188432000001

Found 31 metabolites which its exact mass value is equals to given mass value 483.1188432000001, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Nicergoline

[(2S,4R,7R)-2-methoxy-6,11-dimethyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),9,12,14-tetraen-4-yl]methyl 5-bromopyridine-3-carboxylate

C24H26BrN3O3 (483.1157426000001)

Nicergoline is only found in individuals that have used or taken this drug. It is an ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. It has been suggested to ameliorate cognitive deficits in cerebrovascular disease. [PubChem]Nicergoline acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation. Therefore the mechanism of Nicergoline is to increase vascular circulation in the brain, thereby enhancing the transmission of nerve signals across the nerve fibres, which secrete acetylcholine as a neural transmitter. C - Cardiovascular system > C04 - Peripheral vasodilators > C04A - Peripheral vasodilators > C04AE - Ergot alkaloids C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002491 - Central Nervous System Agents > D018697 - Nootropic Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents Nicergoline, an ergoline derivative ester of bromonicotinic acid, is a potent, selective and orally active antagonist of α1A-adrenoceptor. Nicergoline has vasodilator effects. Nicergoline also has ameliorative effects on cognitive function in mouse models of Alzheimer's disease[1][2].

Nicergoline

C24H26BrN3O3 (483.1157426000001)

C - Cardiovascular system > C04 - Peripheral vasodilators > C04A - Peripheral vasodilators > C04AE - Ergot alkaloids C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002491 - Central Nervous System Agents > D018697 - Nootropic Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents relative retention time with respect to 9-anthracene Carboxylic Acid is 0.982 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.978 Nicergoline, an ergoline derivative ester of bromonicotinic acid, is a potent, selective and orally active antagonist of α1A-adrenoceptor. Nicergoline has vasodilator effects. Nicergoline also has ameliorative effects on cognitive function in mouse models of Alzheimer's disease[1][2].

Cys Cys Met Gln

(2S)-2-[(2S)-2-[(2R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-sulfanylpropanamido]-4-(methylsulfanyl)butanamido]-4-carbamoylbutanoic acid

C16H29N5O6S3 (483.12798940000005)

Cys Cys Gln Met

(2S)-2-[(2S)-2-[(2R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-sulfanylpropanamido]-4-carbamoylbutanamido]-4-(methylsulfanyl)butanoic acid

C16H29N5O6S3 (483.12798940000005)

Cys Met Cys Gln

(2S)-2-[(2R)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-4-(methylsulfanyl)butanamido]-3-sulfanylpropanamido]-4-carbamoylbutanoic acid

C16H29N5O6S3 (483.12798940000005)

Cys Met Gln Cys

(2R)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-4-(methylsulfanyl)butanamido]-4-carbamoylbutanamido]-3-sulfanylpropanoic acid

C16H29N5O6S3 (483.12798940000005)

Cys Gln Cys Met

(2S)-2-[(2R)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-4-carbamoylbutanamido]-3-sulfanylpropanamido]-4-(methylsulfanyl)butanoic acid

C16H29N5O6S3 (483.12798940000005)

Cys Gln Met Cys

(2R)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-4-carbamoylbutanamido]-4-(methylsulfanyl)butanamido]-3-sulfanylpropanoic acid

C16H29N5O6S3 (483.12798940000005)

Met Cys Cys Gln

(2S)-2-[(2R)-2-[(2R)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-sulfanylpropanamido]-3-sulfanylpropanamido]-4-carbamoylbutanoic acid

C16H29N5O6S3 (483.12798940000005)

Met Cys Gln Cys

(2R)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-sulfanylpropanamido]-4-carbamoylbutanamido]-3-sulfanylpropanoic acid

C16H29N5O6S3 (483.12798940000005)

Met Gln Cys Cys

(2R)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-4-carbamoylbutanamido]-3-sulfanylpropanamido]-3-sulfanylpropanoic acid

C16H29N5O6S3 (483.12798940000005)

Gln Cys Cys Met

(2S)-2-[(2R)-2-[(2R)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-sulfanylpropanamido]-3-sulfanylpropanamido]-4-(methylsulfanyl)butanoic acid

C16H29N5O6S3 (483.12798940000005)

Gln Cys Met Cys

(2R)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-sulfanylpropanamido]-4-(methylsulfanyl)butanamido]-3-sulfanylpropanoic acid

C16H29N5O6S3 (483.12798940000005)

Gln Met Cys Cys

(2R)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-4-(methylsulfanyl)butanamido]-3-sulfanylpropanamido]-3-sulfanylpropanoic acid

C16H29N5O6S3 (483.12798940000005)

Flucycloxuron

Flucycloxuron, (Z)-

C25H20ClF2N3O3 (483.1161184)

N-[(1R,2R)-2-amino-1,2-diphenylethyl]-N-[3,5-bis(trifluoromethyl)phenyl]-Thiourea

C23H19F6N3S (483.1203806000001)

Azlocillin sodium

Azlocillin sodium salt

C20H22N5NaO6S (483.1188432000001)

D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic

N-[2-(3,4-dimethoxyphenyl)ethyl]-2-[3-(4-fluorophenyl)-2,4-dioxo-1-thieno[3,2-d]pyrimidinyl]acetamide

C24H22FN3O5S (483.12641340000005)

N-(9-ethyl-3-carbazolyl)-2-[5-(4-morpholinylsulfonyl)-2-thiophenyl]acetamide

C24H25N3O4S2 (483.128641)

3-acetamido-N-[4-(4-methylsulfonylphenyl)-2-thiazolyl]-3-phenyl-N-prop-2-enylpropanamide

C24H25N3O4S2 (483.128641)

4-[[3-[(2-chlorophenyl)methyl]-5-cyclopropyl-7-triazolo[4,5-d]pyrimidinyl]amino]-N,N-dimethylbenzenesulfonamide

C22H22ClN7O2S (483.12441420000005)

N-[2-[(2R,5S,6S)-5-[(3,4-dichlorophenyl)carbamoylamino]-6-(hydroxymethyl)oxan-2-yl]ethyl]-4-fluorobenzamide

C22H24Cl2FN3O4 (483.1127816)

N-[2-[(2S,5S,6R)-5-[(3,4-dichlorophenyl)carbamoylamino]-6-(hydroxymethyl)oxan-2-yl]ethyl]-4-fluorobenzamide

C22H24Cl2FN3O4 (483.1127816)

N-[2-[(2S,5R,6R)-5-[[(3,4-dichloroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-4-fluorobenzamide

C22H24Cl2FN3O4 (483.1127816)

N-[2-[(2R,5R,6R)-5-[[(3,4-dichloroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-4-fluorobenzamide

C22H24Cl2FN3O4 (483.1127816)

N-[2-[(2R,5R,6S)-5-[[(3,4-dichloroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-4-fluorobenzamide

C22H24Cl2FN3O4 (483.1127816)

N-[2-[(2S,5S,6S)-5-[(3,4-dichlorophenyl)carbamoylamino]-6-(hydroxymethyl)oxan-2-yl]ethyl]-4-fluorobenzamide

C22H24Cl2FN3O4 (483.1127816)

N-[2-[(2S,5R,6S)-5-[[(3,4-dichloroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-4-fluorobenzamide

C22H24Cl2FN3O4 (483.1127816)

N-[2-[(2R,5S,6R)-5-[[(3,4-dichloroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-4-fluorobenzamide

C22H24Cl2FN3O4 (483.1127816)

5-bromo-3-pyridinecarboxylic acid [(6aS,9R,10aS)-10a-methoxy-4,7-dimethyl-6a,8,9,10-tetrahydro-6H-indolo[4,3-fg]quinoline-9-yl]methyl ester

C24H26BrN3O3 (483.1157426000001)

Sermion

C24H26BrN3O3 (483.1157426000001)

D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002491 - Central Nervous System Agents > D018697 - Nootropic Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents